Apollo Health Ventures — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease.
AI & Machine LearningBiotechDeep TechHealthtech
Samir Ounzain(Chief Executive Officer (CEO) & Co-founder)inDaniel Blessing(Chief Scientific Officer (CSO) & Co-founder)inRichard Law(Chief Business Officer (CBO))inEric Adam(Chief Operating Officer (COO))inJordan Shin(Chief Medical Officer (CMO))inJérôme Andries(Chief Financial Officer (CFO))in
Co-investorsBroadview VenturesSofinnova Partners+ND Capital4see VenturesLifelinkHumboldt
Abalos Therapeutics develops immunotherapy treatments using arenavirus-based approaches for cancer.
BiotechHealthtech
Co-investorsVentura BioMed InvestorsBoehringer Ingelheim Venture Fund
Bloom Science is a clinical-stage biotech company developing live biotherapeutic products that replicate the effects of the ketogenic diet through the gut-brain axis.
BiotechDeep TechDigital HealthSan Diego, US
Co-investorsALS Investment FundJoyance PartnersPsyMed VenturesSocial StartsLeaps by Bayer
Ochre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models.
AI & Machine LearningBiotechHealthtechMedical DevicesLondon, GB
Quin Wills(Founder/CSO)inJack O'Meara(Founder)in
BoardChinwe UkomaduElaine SullivanEliot ForsterJack Castle
Co-investorsBackedBeast VenturesCoastCapEntrepreneur FirstExpaGaingels+18 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
























__Twitter.png)